scispace - formally typeset
Journal ArticleDOI

Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.

Reads0
Chats0
TLDR
These guidelines are meant to be a practical reference for the pathologist and recommend that immunohistochemical markers have either sensitivity or specificity greater than 80% for the lesions in question.
Abstract
Context.—Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. Objective.—To provide updated practical guidelines for the pathologic diagnosis of MM. Data Sources.—Pathologists involved in the International Mesothelioma Interest Group and others with an interest in the field contributed to this update. Reference material includes peer-reviewed publications and textbooks. Conclusions.—There was consensus opinion regarding (1) distinction of benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiation of epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the diagnosis of MM,...

read more

Citations
More filters
Journal ArticleDOI

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

TL;DR: The ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up for malignant pleural mesothelioma show clear trends in survival and morbidity and recommend a 6-month to 12-monthFollow-up period for diagnosis and treatment.
Journal ArticleDOI

The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.

TL;DR: Several promising observations in mesothelioma pathology and genetics have been made in the past decade and are now the subject of further investigation to determine if they can be validated in ways that will significantly impact clinical practice.
Journal ArticleDOI

BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

TL;DR: BAP1 immunostain represents an excellent biomarker with an unprecedented specificity in the distinction between benign and malignant mesothelioma and other mesothelial proliferations and is commonly associated with homozygous BAP1 deletion.
References
More filters
Journal ArticleDOI

Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.

TL;DR: In this paper, the authors investigated the progression of pancreatic and gastric peritoneal carcinomatosis (PC) from non-gynecologic malignancies, and found that the survival rates were mainly affected by the initial stage (98 months for Stage I with malignant peritone granulations less than 5 mm in greatest dimension, versus 37 months for stage IV with large, malignant malignancy more than 2 cm in largest dimension) The presence of ascites was associated with poor survival of patients with gastric or pancreatic carcinoma Differentiation of the
Journal ArticleDOI

A comprehensive analysis of PAX8 expression in human epithelial tumors.

TL;DR: Results show that PAX8 is a highly sensitive marker for thyroid, renal, Müllerian, and thymic tumors, and is an excellent marker for confirming primary tumor site.
Journal ArticleDOI

Application of mesothelin immunostaining in tumor diagnosis.

TL;DR: It is found that, in some instances, mesothelin immunostaining can assist in the diagnosis of these tumors, and this indicates that this marker may have some diagnostic utility in discriminating between neoplastic and nonneoplastic pancreatic ductal epithelium.
Related Papers (5)